CH.B

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Retrieved on: 
Saturday, April 6, 2024
MB, TGS, High, Science, CH.B, Risk, Research, American College, MACE, Professional corporation, IPE, JACC, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • There are no treatments currently approved to reduce residual CV risk on top of contemporary medical therapy in patients with high Lp(a) levels.
  • In this subanalysis, there were 7,026 REDUCE-IT patients with baseline Lp(a) data and a median Lp(a) value of 11.6 (Q1-Q3: 5.0-37.4) mg/dL.
  • Importantly, the treatment benefit of IPE was evident across subgroups with both high (≥50 mg/dL) and low (
  • Limitations are that randomization was not stratified by baseline LDL-C, however, baseline characteristics were similar among the two baseline LDL-C subgroups.

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
MB, Amarin, REDUCE, CH.B, Risk, Patient, SVP, Research, American College, EPA, Abadir Umar ar-Rida, MACE, Professional corporation, IPE

DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.

Key Points: 
  • These data demonstrate the molecule’s impact in reducing patients’ residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels.
  • Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."
  • “This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community’s understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally,” concluded Abadir.
  • Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

Retrieved on: 
Thursday, October 26, 2023
CH.B, MB, Plasma, Health, DHA, SVP, History, Eicosapentaenoic acid, American Heart Association, Amarin, Diabetes, Research, Metabolic syndrome, EPA, Abadir Umar ar-Rida, Risk, IPE, Abstract, Professional corporation, AHA, Molina Healthcare, Patient, Cardiovascular disease, Pharmaceutical industry, Dietary supplement

This subgroup was almost exclusively comprised of patients with established cardiovascular disease.

Key Points: 
  • This subgroup was almost exclusively comprised of patients with established cardiovascular disease.
  • Lastly, an abstract describing the demographic/clinical characteristics of US patients taking icosapent ethyl, focusing on those with diabetes, will also be presented.
  • These and other new findings will be presented by a variety of international academic collaborators based on research or analyses supported by Amarin.
  • Featured Amarin-supported abstracts to be presented at AHA Scientific Sessions 2023 include:
    Michael Miller, Deepak L. Bhatt, Eliot A. Brinton, Terry A Jacobson et al...

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Retrieved on: 
Wednesday, July 26, 2023
Abstract, Risk, ESC Congress, MB, European Society of Cardiology, EST, Research, Biomarker, CH.B, MACE, Amarin, Professional corporation, IPE, Congress, EPA, Ethyl eicosapentaenoic acid, Patient, Eicosapentaenoic acid, ESC, SVP, MPH, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.
  • This new research includes, along with other topics, the review of the contribution of eicosapentaenoic acid (EPA) and other biomarkers to MACE reduction by icosapent ethyl (IPE).
  • Featured Amarin-supported abstracts to be presented at ESC Congress 2023 include:
    -Available: August 26 at 9:24 CET (3:24 a.m. EST) in Lisbon Room
    Session: What's new in lipid lowering?
  • CH.B., SVP, Chief Medical Officer and Head of Global Medical Affairs, Amarin.

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

Retrieved on: 
Friday, May 12, 2023
CT, Plaque, Myocardial infarction, Diabetes, MB, Macrophage, NIRF, Triglyceride, Cardiovascular disease, Radiology, CAD, CTA, Research, Loyola University, IVUS, CH.B, Atherosclerosis, Amarin, Professional corporation, European Heart Journal: Cardiovascular Imaging, Ethyl eicosapentaenoic acid, Animal, Computed tomography angiography, Patient, European Heart Journal, Molecular imaging, American Heart, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiovascular Imaging, and plaque progression, which was presented at the American Heart Association’s Vascular Discovery 2023 meeting in Boston, MA, May 10-13.

Key Points: 
  • EVAPORATE demonstrated that in statin-treated patients, VASCEPA/VAZKEPA significantly reduced plaque burden measured by serial coronary computed tomography angiography (CTA) compared with placebo.
  • VASCEPA/VAZKEPA improved mean distal segment FFRCT at 9- and 18-months follow-up compared with placebo (P = 0.02, P = 0.03 respectively).
  • “These new findings from two different studies provide important mechanistic information about VASCEPA/VAZKEPA and further elucidate its value in reducing cardiovascular events in at-risk patients,” said Nabil Abadir, MB.
  • We are proud to add to the body of research that further demonstrates the benefit of VASCEPA/VAZKEPA."